Other cytostatics All Financial Data in US $ (mln)
Worldwide  
  Overview  

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

EvaluatePharma® Coverage of Marketed and Pipeline Products
Product Count
Other cytostatics1 2,770
Therapy Area Worldwide Sales (2007/08)
Annual Sales WW - Sales Growth per Year (%)
Rank2 Company Product 2007 2008 2008
Other cytostatics3       6,838 9,255   +35%  
Note: Shaded Cells4
Product Worldwide Market Share 2008
Annual Sales WW - Sales
Rank5 Therapeutic Subcategory Company Product 2008
1 Other cytostatics Novartis Gleevec/Glivec 3,6706
2 Other cytostatics Celgene Revlimid 1,3257
3 Other cytostatics Roche Tarceva 1,1248
Other       3,136  
Total9       9,255  
Top 3 Marketed Products by Therapy Area in 2008
Annual Sales WW - Sales Growth per Year (%) Group share (%)
Rank10 Product Generic Name Company 2007 2008 2008 2007 2008
Other cytostatics 1 Gleevec/Glivec imatinib mesylate Novartis 3,05011 3,67012 +20% 45% 40%
2 Revlimid lenalidomide Celgene 77413 1,32514 +71% 11% 14%
3 Tarceva erlotinib hydrochloride Roche 88615 1,12416 +27% 13% 12%
Other         2,128 3,136   +47%   31% 34%  
Total17         6,838 9,255   +35%   100% 100%  
Note: Shaded Cells18

Register to access more FREE content:

  • Top 5 Products Worldwide Sales 2009
  • Top 5 Products Market Share 2009
  • Download to Excel
  • Search 2 yrs of company press releases